Cannabidiol Successful Therapy for Developmental and Epileptic Encephalopathy Related to CYFIP2
Jessyca Thays Melo de Andrade Ramos1
Rosiane da Silva Fontana2
Cassio Luiz de Carvalho Serão3
Fernando Kok4
Dafne Dain Gandelman Horovitz5
Authors Info & Affiliations
Abstract
Background:
The knowledge about the molecular basis of epilepsies has increased enormously with the advent of next-generation sequencing (NGS) technology, and CYFIP2 is one of the many genes recently recognized and associated with epilepsy. Pathogenic variants in CYFIP2 cause Developmental and Epileptic Encephalopathy 65 (DEE65), which is characterized by hypotonia, profound developmental delay, and epilepsy.
Case Presentation:
Herein, we report a 3-year-old male with an early onset epileptic encephalopathy (Ohtahara syndrome) evolving to Lennox-Gastaut syndrome refractory to several antiseizure medications. Whole exome sequencing (WES) disclosed a heterozygous pathogenic variant p.(Arg87Cys) in CYFIP2, which occurred as a de novo event. After the introduction of cannabidiol, the patient remained seizure-free for 16 months and had a marked electroencephalographic improvement.
Conclusion:
Cannabidiol might be a therapeutic option for CYFIP2-related epilepsy
